<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.peertechzpublications.org/assets/xsl/oaitohtml.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
										<responseDate>2026-05-10T12:20:24Z</responseDate>
										<request verb="GetRecord" metadataPrefix="oai_dc" identifier="oai:www.peertechzpublications.org:10.17352/2455-8141.000018">https://www.peertechzpublications.org/oai-pmh</request><GetRecord><record>
								<header>
									<identifier>oai:www.peertechzpublications.org:10.17352/2455-8141.000018</identifier>
									<datestamp>2017-05-04</datestamp>
									<setSpec>PTZ.Allergy:VOL3</setSpec>
								</header>
								<metadata>
									<oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
										<dc:title>
										The Benefit of Montelukast in Atopic Dermatitis Induced by Food Allergies
										</dc:title><dc:creator>Isaac Melamed</dc:creator><dc:creator> Lacey Robinson</dc:creator><dc:creator>Melinda Heffron</dc:creator><dc:description>&lt;p&gt;&lt;strong&gt;Background:&lt;/strong&gt; Cysteinyl leukotriene levels are elevated in patients with atopic dermatitis, which can lead to eosinophilic infiltration of the gastrointestinal tract.&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective:&lt;/strong&gt; We examined the role that montelukast (a leukotriene receptor antagonist) might play in improving symptoms of atopic dermatitis induced by food allergies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods:&lt;/strong&gt; We conducted a randomized, double-blind, placebo-controlled, parallel group study in 20 children, aged 1 to 8 years, with 4 study visits every 3 weeks for 9 weeks. Primary inclusion criteria consisted of: 1) positive reactivity to food (indicated by skin or RAST test); 2) 10–25 % body area affected with atopic dermatitis; and 3) gastrointestinal symptoms. Liquid cetirizine and 1% hydrocortisone cream were both given as rescue medications for atopic dermatitis flare-ups. Pruritis and atopic dermatitis flare-up scores were used to collect clinical data. Laboratory values for nerve growth factor were evaluated pre- and post-treatment.&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results:&lt;/strong&gt; Our main endpoints were the effects of montelukast on the clinical presentation of atopic dermatitis. When comparing the treatment group to placebo, we noted a significant reduction in the pruritis score (p=0.002); a trend toward a reduction in the use of rescue medication (cetirizine: p=0.056; hydrocortisone cream: p=0.056); and a reduction in the level of nerve growth factor; mean values: placebo=3.06 to montelukast=2.59.&lt;span style="white-space:pre"&gt;	&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion:&lt;/strong&gt; The inflammatory pathway triggered by food allergies that may lead to atopic dermatitis can be modulated with montelukast. Furthermore, nerve growth factor may play a role in the pathogenesis of atopic dermatitis and montelukast may modify this pathway.&lt;/p&gt;</dc:description>
										<dc:publisher>Global Journal of Allergy - Peertechz Publications</dc:publisher>
										<dc:date>2017-05-04</dc:date>
										<dc:type>Research Article</dc:type>
										<dc:identifier>https://doi.org/10.17352/2455-8141.000018</dc:identifier>
										<dc:language>en</dc:language>
										<dc:rights>Copyright © Isaac Melamed et al.</dc:rights>
									</oai_dc:dc>
								</metadata>
							</record></GetRecord>
						</OAI-PMH>
